obesity drug news today glp-1 october 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 Harnessing GLP-1 Receptor Agonists for

Additionally, researchers use preclinical models to examine how the metabolic effects of dual gastric inhibitory polypeptide (GIP)/GLP-1R agonists such as tirzepatide mediate anti-inflammatory and anti-fibrotic benefits, such as in metabolic dysfunction-associated steatotic liver disease

These days, its nearly impossible to avoid chatter about GLP-1s

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al

Before asking participants about their expectations for the drugs impacts on the food system, all participants were given a brief background on the topic, which said: GLP-1 drugs decrease users appetite, which results in fewer calories consumed

Diabetes: a tipping point in neurodegenerative diseases